Comparing robotic, video-assisted, and open lung surgery after chemo-immunotherapy for lung cancer
Official title: An International Multicenter Retrospective Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy
Run by Scientific Institute San Raffaele · NCT06626243 · Data updated 2026-11-12
This study looks at how well robotic, video-assisted, and open lung surgeries work for people with lung cancer after they’ve had chemo-immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 140 (estimated) |
| Sponsor | Scientific Institute San Raffaele Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 6 sites (Miami, Florida and 5 other locations) |
| Status | Recruiting |
| Started | September 30, 2024 |
| Main results expected | February 15, 2025 |
| Study ends | October 15, 2025 |
| Registry record updated | November 29, 2024 |
| Trial ID | NCT06626243 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older diagnosed with locally advanced and resectable NSCLC who have undergone neoadjuvant chemo-immunotherapy and subsequent lung resection.
✕Probably not a fit
Patients who are under 18 years old or those who have not received neoadjuvant chemo-immunotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study analyzes medical records from patients diagnosed with locally advanced and resectable non-small cell lung cancer (NSCLC) who underwent lung resection using robotic, video-assisted thoracoscopic surgery (VATS), or open surgery after receiving neoadjuvant chemo-immunotherapy. The study aims to evaluate the short-term outcomes and oncologic efficacy of these surgical approaches. By examining data from five international centers, it seeks to provide insights into the feasibility and effectiveness of these techniques in a real-world setting.
Why it matters
Potential benefit: If successful, this study could help identify the most effective surgical approach for patients with NSCLC after chemo-immunotherapy, potentially improving patient outcomes.
How similar studies have gone: While there is limited research directly comparing these surgical approaches post-chemo-immunotherapy, similar studies have shown promising results in evaluating surgical techniques for lung cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of clinical or pathological stage IIB (T1-2, hilar N1, M0) and III (any T, N1-2, M0) NSCLC surgically treated with robotic, VATS and open approach with radical intent from 1st of January 2016 to 31st of March 2024 * Received neoadjuvant chemo-immunotherapy or immunotherapy alone * Age \>= 18 years old at the moment of surgery Exclusion Criteria: * Age \<18 years old at the moment of surgery
Where it's running
-
Baptist Health South Florida
Miami, Florida, United States Recruiting -
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting -
West Virginia University
Morgantown, West Virginia, United States Recruiting -
Istituto Clinico Humanitas
Rozzano, Milan, Italy Recruiting -
Scientific Institute Ospedale San Raffaele
Milan, Italy Recruiting -
Regina Elena National Cancer Institute
Rome, Italy Recruiting
Study contacts
- Study coordinator: Pierluigi Novellis, Medical Doctor
- Email: novellis.pierluigi@hsr.it
- Phone: 0226437202
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.